Betalin Therapeutics

Betalin Therapeutics is an Israel-based biotechnology company developing a proprietary Engineered Micro-Pancreas (EMP) to treat diabetes. The company's technology utilizes a biological 3D scaffold, known as the Micro-Organ Matrix (MOM), designed to provide a supportive micro-environment for transplanted pancreatic islets. By implanting this micro-organ under the skin, the EMP aims to restore the body's natural, glucose-regulated insulin production. This approach seeks to overcome limitations of traditional treatments, such as the Edmonton Protocol, by improving cell viability and avoiding the need for highly specialized liver-based transplantation procedures or systemic immune suppression.

The technology is intended to liberate diabetic patients from the burden of daily insulin injections, constant blood glucose monitoring, and associated dietary constraints. By restoring physiological insulin regulation, the EMP aims to prevent severe short-term complications like hypoglycemia and long-term health risks including stroke, heart disease, and organ failure. Supported by funding from the European Innovation Council and the Horizon 2020 program, the company has engaged in research collaborations with medical centers to advance the development and clinical evaluation of its regenerative therapy.